Good news!
I had sold all my shares, but may pick up a new position. They have a subgroup that may be good enough for approval. Since HLA2 is only in about half the patients and Merthylated is also only in less than half we are getting to a smaller percentage. . I don't know what It is but on the negative side for maybe 70% of Glio, patients it will not be an effective treatment. Will certainly have to run a new phase III. Definitely good news but not great, IMHO. but the stock lives. Will wait to see how far it opens up but will not chase it to far tomorrow.